The Role of Echocardiography in Early Detection and Evaluation of Treatment Response: Predicting Prognosis in Patients With Pulmonary Arterial Hypertension

 

 

On-demand CME/CE webcast previously recorded from the September 25, 2021, Hospital Medicine Summit

PROGRAM OVERVIEW

Pulmonary arterial hypertension (PAH), a rare yet potentially fatal progressive disease associated with increased pulmonary vascular resistance and pulmonary artery pressure, exerts a considerable burden on quality of life. During the early stages of the disease, patients often present with nonspecific symptoms and subtle physical signs, which can result in late detection and diagnosis. Transthoracic echocardiography is a noninvasive approach used for screening patients with symptoms or risk factors for pulmonary hypertension, including connective tissue disease, and may also provide clinicians with information on disease etiology and prognosis, information which can be used to tailor treatment approaches to ensure better outcomes. In conjunction with early detection and evaluation of treatment response, echocardiography may also predict prognosis in patients with PAH. Today, there are several approved medications that target 3 distinct pathological pathways in PAH, including the prostacyclin, endothelin, and nitric oxide pathways. Currently, there is a growing trend to combine agents from these different therapeutic classes to target multiple pathologic pathways, as this may improve efficacy and optimize clinical outcomes.

Given the diverse, complex, and nonspecific presentation of PAH, a multidisciplinary approach is needed to ensure optimal diagnostic assessment and adherence to combination therapy. This program will provide clinicians with an understanding of echocardiography assessment, increase awareness of recent data from trials on combination therapy, and improve understanding of a patient-centered and multidisciplinary approach to PAH care.

Faculty Speaker

John Ryan, MD, MB, BCh
Director, Pulmonary Hypertension Comprehensive Care Center
Medical Director, Cardiovascular Medical Unit
University of Utah Hospital
Faculty Director of Cardiology Education
University of Utah School of Medicine
Salt Lake City, Utah

 

Release date: November 15, 2021
Expiration date: November 15, 2022
Estimated time to complete activity: 1 hour

 

 TARGET AUDIENCE

This educational activity has been designed to meet the needs of physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists who practice in hospital, internal medicine, and chronic-care settings.

 LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Describe the role of echocardiography in the early diagnosis of PAH and prediction of prognosis in patients with high-level risk factors
  • Summarize recent data regarding the impact of combination therapy on risk reduction and prognosis in patients with PAH
  • Discuss the value of patient-focused management and interdisciplinary approaches to support the care of patients with PAH
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME/CE credit for this enduring activity. During the period of November 15, 2021, through November 15, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%. Pharmacists must check the CPE monitor for their credits within 60 days of the activity.

MEDIA

Internet

PHYSICIAN CONTINUING EDUCATION

Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Global Education Group designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Numbers – 0530-9999-21-290-H01-P.)

This is a knowledge-based activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or hms@integrityce.com.

For information about ACPE or ANCC accreditation of this activity, please contact Global at (303) 395-1782 or cme@globaleducationgroup.com.

SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLOSURE OF CONFLICTS OF INTEREST (COI)

Integrity Continuing Education and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

FACULTY DISCLOSURES

John Ryan, MD, MB, BCh
Consulting Fees: Bayer, Janssen PH, United Therapeutics
Fees for Non-CME/CE Services: Bayer, Janssen PH, United Therapeutics

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Liddy Knight, Kim Rodriguez, Rhys Williams, RN, MSN, FNP, Maria Rovere, MTSC, and Patima Tanapat, PhD, reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

PROVIDER STATEMENT

This CME activity is provided by Integrity Continuing Education.
This CEU/CNE activity is jointly provided by Global Education Group and Integrity Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

 

Continue to Pretest